IDENTIFICATION OF NOVEL MEANS TO OVERCOME RESISTANCE TO VENETOCLAX IN AML
Lector: Dr Michal Smida
Institution: Masaryk University, Faculty of Medicine
Field: Biomedical Sciences
About the project
Acute myeloid leukemia (AML) is a disease of poor survival and limited therapy options, primarily relying on chemotherapy. Venetoclax is a novel promising BCL-2 inhibitor, whose efficacy suffers from resistance. Using drug profiling and CRISPR/Cas9 screening, we will identify drugs able to synergize with venetoclax or able to revert venetoclax-resistance. This may reveal unique targets for novel effective targeted therapy to achieve stronger responses compared to single Venetoclax treatment.
Science is about innovation and discovery and requires a great deal of inquisition. Scientific research is challenging and you must have a great deal of determination to uncover answers to your specific question. I am a naturally curious individual and I am very passionate about my field of research.
What do I like most about Brno
I love how Brno is a cosmopolitan student city bringing together scholars and students from all across the world. It has a diverse group of backgrounds and has a rich history in Science which makes me feel as if we are quite literally standing on the shoulders of giants.